This episode explores the significant market shift toward molecular and genetic diagnostics projected for 2026. We analyze the key drivers behind this trend and outline how MedTech and IVD companies can create value in high-growth areas like oncology, infectious disease, personalized medicine, and the development of integrated data platforms that provide actionable clinical insights.

- Why is diagnostic spending shifting dramatically towards molecular and genetic tests by 2026?

- What are the primary drivers making advanced genomic testing more accessible?

- How can MedTech companies create value in oncology beyond traditional diagnostics?

- What is the critical role of point-of-care molecular testing in managing infectious diseases?

- Why are integrated data platforms and AI becoming essential for the next wave of diagnostics?

- How does personalized medicine change the strategy for diagnostic companies?

- What are the opportunities in companion diagnostics and liquid biopsies?

- Is your company prepared to navigate the regulatory complexities of these advanced IVDs?

Pure Global offers end-to-end regulatory consulting for MedTech and IVD companies, helping you access over 30 global markets. We leverage advanced AI and data tools to develop efficient regulatory strategies, compile technical dossiers, and streamline submissions, minimizing costs and accelerating your time to market. Whether you're a startup or a multinational, our local experts provide the support needed to navigate complex international requirements for cutting-edge diagnostics. Contact us at [email protected], visit https://pureglobal.com/, or explore our FREE AI tools and database at https://pureglobal.ai.